Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.87 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588149 | 0.93 | DRD4 (1.00) | DRD4SIGMAR1MAPTL3MBTL1DRD2 | |
| SCHEMBL6030916 | 0.91 | MAPT (0.83) | DRD4SIGMAR1MAPTL3MBTL1DRD2 | |
| Hydrochloric Acid SCHEMBL6030550 | 0.89 | MAPT (0.81) | DRD4SIGMAR1MAPTL3MBTL1DRD2 | |
| SCHEMBL6031812 | 0.89 | DRD4 (1.00) | DRD4SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL12861757 | 0.86 | DRD4 (0.79) | DRD4SIGMAR1DRD2DRD3KDM4E | |
| SCHEMBL22532699 | 0.86 | DRD4 (0.79) | DRD4SIGMAR1L3MBTL1DRD2DRD3 | |
| SCHEMBL6030721 | 0.85 | KDM4E (0.72) | DRD4SIGMAR1MAPTKDM4EALDH1A1 | |
| SCHEMBL7604485 | 0.84 | DRD4 (0.77) | DRD4SIGMAR1MAPTDRD2DRD3 | |
| SCHEMBL3242187 | 0.84 | DRD4 (0.77) | DRD4SIGMAR1DRD2DRD3HTR2C | |
| SCHEMBL3242189 | 0.84 | DRD4 (0.77) | DRD4SIGMAR1DRD2DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101887-B2 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2006-09-05 | — | — | US | claimed |
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | claimed |
| EP-0960106-B1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORP (US) | 2004-05-06 | — | — | EP | claimed |
| US-20040083447-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-04-29 | — | — | US | claimed |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-06-26 | — | — | US | claimed |
| US-6426347-B2 | FOR PREVENTION OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION | 2002-07-30 | — | — | US | claimed |
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | THURKAUF ANDREW (US) | 2002-01-17 | — | — | US | claimed |
| JP-2001521492-A | — | — | 2001-11-06 | — | — | JP | claimed |
| EP-0960106-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | claimed |
| EP-1963296-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007066163-A2 | OPTICALLY ACTIVE CARBAMATES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvanosan Mukodo Reszvenytarsasag (HU) | 2007-06-14 | — | — | WO | disclosed |
| US-7101887-B2 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | NEUROGEN CORPORATION (US) | 2005-10-27 | — | — | US | disclosed |
| EP-0960106-B1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORP (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6656943-B2 | In the treatment or prevention of psychotic disorders such as schizophrenia psychotic depression, mania and other central nervous system diseases | NEUROGEN CORPORATION | 2003-12-02 | — | — | US | disclosed |
| US-6172229-B1 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-0960106-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5859246-A | TREATING NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998033784-A1 | 1-PHENYL-4-BENZYLPIPERAZINES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS (D4) | NEUROGEN CORPORATION (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239799-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype | DRD2, DRD4, HTR2C | DRD4 2/4885SIGMAR1 96/4885MAPT 1859/4885 |
| US-20020007064-A1 | 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | DRD4 4/4885SIGMAR1 91/4885MAPT 2147/4885 |
| US-20030119851-A1 | 1-phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands | HTR2C, GRIN2C, HTR1A | DRD4 4/4885SIGMAR1 91/4885MAPT 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.